Indeed, although there was no decrease in food intake or body weight associated with treatment induction, due to these adverse effects being on-target and mediated exclusively through TLR7 in mouse, treatment groups began to diverge significantly during the cachexia stage. The gene discussed is TLR7; the disease is Cachexia.